

Revised Draft Agenda Biocides Working Group Meeting II-2024 10-20 June 2024

The time is indicated in Helsinki time.

10-11 June	10:00-18:00	APCP WG
12 June	10:00-18:00	APCP WG (reserve day)
14 June	10:00-16:00	In-situ
11-13 June	10:00-18:00	TOX WG
14 June	10:00-16:00	In-situ
18 June	10:00-18:00	TOX WG (reserve day)
11 June	10:00-17:00	EFF WG
13 June	10:30-18:00	EFF WG
14 June	10:00-16:00	In-situ
17 June	10:30-18:00	EFF WG
18 June	10:30-13:00	EFF WG (reserve day)
14 June	10:00-16:00	In-situ
17-19 June	10:00-18:00	ENV WG
20 June	10:00-18:00	ENV WG (reserve day)



Analytical methods and physico-chemical properties Working Group Chair: Andreas Uphoff		
Item 1 - Welcome and apologies	•	
Nomina Troncomo una apologico	For information	
Item 2 – Administrative issues		
	For information	
Item 3 – Agreement of the agenda		
	For agreemen	
Item 4 – Declarations of potential conflicts of interest in relation	n to the agenda	
14 5 4 4 14 1 4 (14/0 1 000 4	For information	
Item 5 – Agreement on the minutes of WG I 2024		
	For agreemen	
Item 6 - Active Substances		
6.1 Early WG on Muscalure (renewal)		
	For agreemen	
6.2 Early WG on Active chlorine generated from chloride of an	nbient water by electrolysis	
	For agreemen	
Item 7 – Union Authorisations		
7.1 UA family product containing Transfluthrin PT18		
	This agenda item will not be discussed as there are no open points	
7.2 UA family product containing L-(+)-lactic acid PT3		
	This agenda item will not be discussed as there are no open points	
7.3 UA family product containing Chlorocresol PT3		
	This agenda item will not be discussed as there are no open points	
Item 8- Technical and guidance related iter		
Item 8- Technical and guidance related item 8.1 In situ recommendations		
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRe	For discussion as 2 document	
8.1 In situ recommendations	For discussion ev 2 document oducts	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal process.	For discussion oducts For discussion of the control of the contro	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRe	For discussion ev 2 document oducts For discussion e	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal pressure as a certain formulation type.	For discussion av 2 document oducts For discussion e For discussion	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal process.	For discussion ev 2 document oducts For discussion e For discussion e For discussion storage testing (overdosing)	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal pressure as a certain formulation type.	For discussion av 2 document oducts For discussion e For discussion	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRecegarding handling "carriers" in the authorisation of biocidal presson and second s	For discussion ev 2 document oducts For discussion e For discussion e For discussion storage testing (overdosing)	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRecegarding handling "carriers" in the authorisation of biocidal presson and second s	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal pressor and service of pre-soaked wipes to a certain formulation type. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing.	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal presson and service of pre-soaked wipes to a certain formulation type. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing.	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For agreement For agreement	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReferegarding handling "carriers" in the authorisation of biocidal process. Allocation of pre-soaked wipes to a certain formulation types. Acceptable active substance degradation threshold during 8.5 Worst case commercial packaging for storage testing 8.6 TAB entry Role of water in peracetic acid solutions	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For agreement For agreement	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReferegarding handling "carriers" in the authorisation of biocidal process. Allocation of pre-soaked wipes to a certain formulation types. Acceptable active substance degradation threshold during 8.5 Worst case commercial packaging for storage testing 8.6 TAB entry Role of water in peracetic acid solutions	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement	
 8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReferegarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation type. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive p. Item 9- AoB. 	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement	
8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRe regarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation typout and the substance degradation threshold during and the substance commercial packaging for storage testing. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive properties.	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement	
 8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReferegarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation type. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive p. Item 9- AoB 	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement For agreement For discussion For discussion For discussion For discussion	
 8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReferegarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation typosta. 8.4 Acceptable active substance degradation threshold during as to some substance. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive positive properties. 9.1 Nanomaterials and Biocides. 	For discussion ev 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement For agreement For discussion For discussion For discussion For discussion	
 8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalReregarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation type. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive properties. 9.1 Nanomaterials and Biocides. 9.2 Review of e-consultations. 	For discussion av 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement For agreement For discussion For information	
 8.1 In situ recommendations 8.2 APCP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRe regarding handling "carriers" in the authorisation of biocidal properties. 8.3 Allocation of pre-soaked wipes to a certain formulation typos. 8.4 Acceptable active substance degradation threshold during. 8.5 Worst case commercial packaging for storage testing. 8.6 TAB entry Role of water in peracetic acid solutions. 8.7 Waiving of test for self-reactive properties and explosive properties. 9.1 Nanomaterials and Biocides. 	For discussion av 2 document oducts For discussion e For discussion storage testing (overdosing) For discussion For agreement For agreement For agreement For discussion For information	



Human Health Working Group Chair: Antero Airaksinen	
Item 1 - Welcome and apologies	
	For information
Item 2 – Administrative issues	
	For information
Item 3 – Agreement of the agenda	For oaroomont
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	For agreement
·	For information
Item 5 – Agreement on the minutes of WG I 2024	
	For agreement
Item 6 - Active Substances	
6.1 Early WG on in situ generated active bromine - ED assessment	
	For agreement
6.2 Early WG on Diuron - ED assessment	
	For agreement
6.3 Early WG on Dazomet renewal	
	For agreement
6.4 Early WG on chlorate as disinfection by-product in AS applications: * Sodium dichloroisocyanurate (anhydrous PT 2, 3, 4, 5, 11 * Sodium dichloroisocyanurate (NaDCC) dihydrate PT 2, 3, 4, 5, 11 * Trichloroisocyanuric acid (TCCA) PT 2, 3, 4, 5, 11	
	For agreement
Item 7 - Union Authorisations 7.1 UA family product containing Transfluthrin PT 18	
	For agreement
7.2 UA family product containing L-(+)-lactic acid PT 3	
This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as there are a This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as the This agenda item will not be discussed as a think agenda it	no open points.
7.3 UA family product containing Chlorocresol PT 3 This agenda item will not be discussed as there are a second containing the containing Chlorocresol PT 3	no onen noints
7.4 Early WG on UA-APPs containing Icaridine, PT 19	то орен ронка.
	For agreement
7.5 Early WG on QUAT-based products, PT 3, 4	



Item 8 – Article 75(1)(g) requests	
8.1 Early WG on Salicylic acid ED assessment	
Item 9- Technical and guidance related items	For agreement
9.1 Cats and pyrethroids - warning sentences	
9.2 Field of use (HH and EFF joint session)	For agreement
	For discussion
9.3 In situ recommendations	For discussion
Item 10- AoB	
10.1 Other information	
	For information



Efficacy Workin Chair: Kasia Szyn	- -
Item 1 - Welcome and apologies	
Item 2 – Administrative issues	For information
	For information
Item 3 – Agreement of the agenda	For agreement
Item 4 – Declarations of potential conflicts of interest in relation to the	ne agenda For information
Item 5 – Agreement on the minutes of WG I 2024	Tormana
Item 6 - Union Authorisations	For agreement
6.1 UA family product containing Transfluthrin PT18	This agenda item will not be discussed as there are no open points.
6.2 UA family product containing L-(+)-lactic acid PT3	······································
J (, , , , , , , , , , , , , , , , , , ,	This agenda item will not be discussed as there are no open points.
6.3 UA family product containing Chlorocresol PT3	
0.45 1.140 144.455 1.111 5740	This agenda item will not be discussed as there are no open points.
6.4 Early WG on UA-APPs containing Icaridine, PT19	For agreement
6.5 Early WG on UA-APPs containing peracetic acid, PT2,3,4	For agreement
Item 7 – Article 75(1)(g) requests	r or agreement
7.1 Formic acid, PT6	
	For agreement
7.2 1,2-Benzisothiazol-3-(2H)-one (BIT), PT6, 13	For agreement
Item 8- Technical and guidance related items	
8.1 Resistance draft guidance	
	For discussion
8.2 TAB proposal – Evaluation of PT 18 products against unicolonia	
8.3 Field of use (HH and EFF joint session)	For discussion
8.4 In situ recommendations	For discussion
	For discussion
8.5 TAB proposal - PT 11 freshwater and/or seawater-based system	ns For discussion



Item 9- AoB

9.1 Other information

For information



Environment Working Group Chair: Sander van der Linden	
Item 1 - Welcome and apologies	
Item 2 – Administrative issues	For information
Maria C. A support of the agree do	For information
Item 3 – Agreement of the agenda	For agreement
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	
Item 5 – Agreement on the minutes of WG I 2024	For information
	For agreement
Item 6 - Active Substances	
6.1 Early WG on in situ generated active bromine - ED assessment	
	For agreement
6.2 Early WG on active chlorine - ED assessment and waiving of data generation	For agreement
6.3 Early WG on Bronopol - Degradation in soil	r or agreement
0.3 Early WG On Bronopor - Degradation in Soil	For agreement
6.4 Early WG on Tosylchloramide sodium - ED assessment	
	For agreement
6.5 Icaridin - revision of toxicity data	
	For agreement
Item 7 - Union Authorisations	
7.1 UA family product containing Transfluthrin PT18	
	For agreement
7.2 UA family product containing L-(+)-lactic acid PT3 This agenda item will not be discussed as there a	are no open points.
7.3 UA family product containing Chlorocresol PT3	, ,
This agenda item will not be discussed as there a	are no open points.
7.4 Early WG on UA-APPs containing Icaridine, PT 19, ERA	
	For agreement
Item 8 – Article 75(1)(g) requests	
8.1 Early WG on Salicylic acid ED assessment	
	For agreement



Item 9- Technical and guidance related items	
9.1 In situ recommendations	
	For discussion
9.2 Revision of ESD PT 18	
	For agreement
9.3 Degradation in manure	
	For agreement
9.4 Qualitative assessment of PAA and HP for releases via the municipal sewer system	
	For agreement
9.5 TAB entry for PEC soil RA considering NER	
	For discussion
9.6 Various exposure risk assessment items for agreement	
	For agreement
9.7 How to model emissions to groundwater from wood preservatives	
	For agreement

Item 10- AoB

10.1 Other information

For information